Immuno-oncology and the advent of immunotherapies, in particular immune checkpoint inhibitors (ICIs), have fundamentally altered the way we treat cancer. Yet only a small subset of patients actually responds to ICIs, and many face significant adverse...
BACKGROUND: Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer. Although immune checkpoint inhibitors (ICIs) have brought new treatment options for advanced patients, a considerable proportion still shows limited resp...
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
Jul 29, 2025
Immunotherapy has revolutionized lung cancer treatment, yet predicting patient response remains a challenge. This study used Raman spectroscopy to differentiate between non-small-cell lung cancer patients with short-lasting and long-lasting responses...
Immunotherapy, in particular checkpoint blockade, has revolutionized the treatment of many advanced cancers. Imaging plays a critical role in assessing both treatment response and the development of immune toxicities. Both conventional imaging and mo...
The role of gut dysbiosis in shaping immunotherapy responses is well-recognized, yet its effect on the therapeutic efficacy of chemotherapy and immunotherapy combinations remains poorly understood. We analyzed gut microbiota in non-small cell lung ca...
BACKGROUND: Immune checkpoint inhibitors (ICIs) are essential first-line treatments for recurrent or metastatic non-small cell lung cancer (NSCLC). However, predicting their effectiveness and the occurrence of immunotherapy-related adverse events (ir...
Primary large B-cell lymphomas of immune-privileged sites, including primary central nervous system lymphoma (PCNSL) and primary testicular lymphoma (PTL), exhibit distinct clinicopathologic features contributing to aggressive behavior and immune eva...
Immune checkpoint inhibitors (ICIs), either as monotherapy (ICI-Mono) or combined with chemotherapy (ICI-Chemo), improves survival in advanced non-small cell lung cancer (NSCLC). However, prospective guidance for choosing between these options remain...
BACKGROUND: PD-1/PD-L1 immunotherapy represents the primary treatment for advanced NSCLC patients; however, response rates to this therapy vary among individuals. This dual-center study aimed to integrate habitat radiomics and multi-instance deep lea...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.